Salofalk GR is a medication used to address inflammatory conditions primarily affecting the bowel. Its main applications include the treatment of acute episodes of mild-to-moderate ulcerative colitis, which is a long-term condition that causes inflammation in the colon and rectum.

---

Quick Facts

• Goal: To help manage inflammation and contribute to symptom relief.
• Primary Application: Treatment of acute episodes of mild-to-moderate ulcerative colitis.
• Long-Term Purpose: Used for the maintenance of remission in ulcerative colitis to assist in preventing recurrence of symptoms.

---

The medication also serves as an option for the maintenance of remission in ulcerative colitis, a phase focused on helping to prevent recurrence of active inflammation and symptoms over time. It is intended to address the underlying inflammation associated with the condition.

Salofalk GR may be indicated for specific cases of Crohn's ileitis and colitis, which are related forms of inflammatory bowel disease, as part of a therapeutic plan to contribute to favorable outcomes. The active component, mesalazine, has an established therapeutic profile for these conditions.

Regulatory References

1. NIH MedlinePlus guidance

Who Can and Cannot Use Salofalk GR?

The eligibility for Salofalk GR (mesalazine granules) is strictly defined by regulatory criteria concerning the patient’s clinical status and age, as documented in official prescribing information.

Eligibility Status	Patient Population / Condition
Contraindicated (Must Not Use)	Hypersensitivity to salicylates, mesalazine, or any product excipients. Severe impairment of hepatic or renal function.
Use Not Recommended	Children below the age of 6 years due to very limited experience and insufficient documentation.

Conditional Use Requirements

The medicine is generally permitted for use in adults and older adults, provided they do not have severe organ impairment. However, mild to moderate impairment of renal or hepatic function requires the medicine to be used with caution and necessitates close monitoring. Conditional use is also required for patients with chronic lung impairment, such as asthma, or a history of allergy to sulfasalazine. Use during pregnancy and breastfeeding is restricted and should only proceed if the potential clinical benefit outweighs the possible risks to the child. For children and adolescents aged 6 to 18 years, documentation for the medicine’s efficacy is limited.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Salofalk GR (Mesalazine) primarily through risks of additive toxicity and pharmacodynamic modifications with certain co-administered substances.

Documented Pharmacodynamic and Toxicity Interactions

Interacting Substance/Class	Official Regulatory Description
Azathioprine, 6-Mercaptopurine, Thioguanine	Possible increase in the myelosuppressive effects; associated with increased 6-thioguanine nucleotide (6-TGN) concentrations [Exposure Modification].
Nephrotoxic Agents (e.g., NSAIDs)	Increased risk of nephrotoxicity and renal adverse reactions.
Coumarin-type Anticoagulants (e.g., Warfarin)	Possible potentiation of the anticoagulant effect, or weak evidence of a decrease in the anticoagulant effect.
Lactulose or similar preparations	May cause a reduction of mesalazine release from the modified-release granules.

Other Documented Interactions

Co-administration with Glucocorticoids may increase undesirable gastric effects, and interactions with Sulfonylureas may increase their blood glucose-lowering effects. The drug or its metabolite, N-Ac-5-ASA, is also officially documented to interfere with certain laboratory procedures, causing spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography. No medicinal products are explicitly designated as contraindicated combinations in the regulatory labels, and no mandatory timing separation rules are documented.

Salofalk GR (mesalazine) acts locally on the cells lining the large intestine, where it engages mechanisms that modulate the inflammatory response. The mechanism involves several distinct actions at the molecular and cellular level.

Modulating Inflammatory Mediators

The medication acts by inhibiting key enzyme systems, including cyclooxygenase (COX) and lipoxygenase (LOX), within mucosal cells. This interaction blocks the enzymatic conversion of precursor molecules into pro-inflammatory lipid mediators such as prostaglandins and leukotrienes. This process limits the initial biochemical signaling associated with the generation of these mediators.

Regulating Genetic Signaling Pathways

Mesalazine influences core cellular control systems by interfering with transcription factors, notably NF-kB (Nuclear Factor-kappa B). NF-kB is a regulatory protein complex that, when active, modulates the gene expression of numerous inflammatory proteins (cytokines). By inhibiting this factor, the drug reduces the transcription of inflammatory proteins, which modulates the mobilization and activity of immune cells.

Scavenging Reactive Oxygen Species

The compound exhibits antioxidant properties, enabling it to directly neutralize highly reactive molecules known as free radicals or Reactive Oxygen Species (ROS). These highly reactive species are byproducts of immune cell activity and contribute to local biochemical changes. This activity limits the chemical stress on mucosal cells, thereby influencing the consequences of oxidative stress on tissue biology.

Salofalk GR (mesalazine modified-release granules) should be taken exactly as prescribed by your doctor. The dosage and duration of treatment are determined by your individual condition (acute episode or maintenance of remission) and its severity. Consistency is essential for therapeutic success.

Administration Instructions

• Do not chew or crush the contents of the sachet, as this will compromise the modified-release coating and may alter the medication's effectiveness.
• Tear open the sachet and pour the entire contents onto your tongue.
• Swallow the granules whole immediately, followed by plenty of fluid, such as a glass or two of water, to wash the medicine down.
• Take your dose(s) at the same time each day to help maintain regularity and ensure consistent drug levels.

---

Dosing Guidelines for Adults

Your doctor will determine the precise dose. General recommendations are as follows:

Indication	Recommended Daily Dosage (Mesalazine)
Acute Ulcerative Colitis	1.5 g to 3 g daily, preferably once a day in the morning or in 2-3 divided doses.
Maintenance of Remission	1.5 g daily, preferably once a day.

Treatment for an acute episode of ulcerative colitis typically lasts up to 8 weeks, but the duration is always determined by your physician. Do not discontinue use without consulting your doctor, even if your symptoms improve.

Research Evidence: Overview of Studies for Salofalk GR

Evidence for Use in Inducing Remission in Ulcerative Colitis

Research exploring the use of Salofalk GR was studied for adults with active Ulcerative Colitis in trials assessing short-term or episodic symptom patterns. The primary research conducted includes randomized, double-blind, multicenter trials, which represent a common study design for evaluating medications. These studies examined specific outcomes related to physical discomfort and inflammatory states, specifically in populations diagnosed with mild-to-moderate active Ulcerative Colitis.

Studies monitored participants over defined, short-term intervals (often around eight weeks). The research examined changes measured during the study period, such as the evolution of symptoms and the healing of the colon lining (Endoscopic Remission), reflecting the absence or reduction of inflammation. Findings describe patterns regarding the proportion of individuals whose status met the criteria for clinical remission at the end of the short study duration. Results apply only to the populations studied; this research provides limited insight into long-term disease progression or the outcomes for individuals whose condition is more severe.

---

Evidence for Use in Maintaining Remission in Ulcerative Colitis

Research has also explored the use of this medication in studies examining conditions characterized by fluctuating manifestations, focusing on outcomes related to avoiding periods of heightened symptoms. The evidence is derived from placebo-controlled trials designed to track participants who had already achieved a stable state of remission. These maintenance studies observe responses over defined time intervals, typically six months to one year.

Studies explored whether continuous use was observed in trials evaluating a lack of heightened symptom activity. Data show patterns related to the observed duration of stable status in participants during the study. Evidence remains limited regarding certain groups, and comparative evidence is lacking in large-scale trials that directly compare the long-term observed stable status of this specific granule formulation against all other mesalazine formulations.

---

What Remains Uncertain in the Research Landscape

While research describes the patterns observed so far, certain limitations in the data for certain groups remain insufficient. For instance, few studies are specifically designed to examine long-term effects beyond a year or two for every individual. Long-term effects are not fully established for all potential scenarios. Comparative evidence is lacking in high-quality trials that directly assess the long-term study outcomes of Salofalk GR against all other treatment options for UC maintenance.

Common questions about Salofalk GR (FAQ)

---

Q: What happens if I take my Salofalk dose later than usual?

A: If you realize you have missed a dose of Salofalk GR, official product information generally recommends that a missed dose should be skipped completely. You would then take your next dose at the normal time it is due. It is not generally advised to take a double dose to compensate for the one that was missed.

---

Q: What is the recommended daily dosage for children aged 6 to 18?

A: According to official regulatory documents, the exact dosage for children aged 6 and older is individually determined by a physician based on the child's body weight. Regulatory guidelines suggest that children over 40 kg body weight may be prescribed the adult dosage. The physician specifies the precise amount needed to either manage an active flare or maintain remission.

---

Q: Can I store the medicine in my bathroom cabinet?

A: Regulatory documents indicate the medicine must be stored in its original sachet packaging and kept in a location where the temperature remains below 25 C and is protected from light. Because bathrooms are often humid and experience frequent temperature fluctuations, they may not consistently meet these cool and dry storage requirements.

---

Q: Is Salofalk GR gluten-free or lactose-free?

A: Salofalk formulations are often officially documented as gluten-free. While regulatory documents list all inactive ingredients, they generally do not contain lactose. Patients are generally advised to review the list of excipients provided in the official package leaflet or Summary of Product Characteristics to confirm the presence of any specific ingredients.

---

Q: How long after taking the granules can I eat a meal?

A: For the granule formulation, official product information does not specify a mandatory time separation between taking the dose and eating a meal. The administration guidelines focus on ensuring the granules are swallowed whole immediately with plenty of fluid. Always follow the specific instructions provided by your doctor.

---

Q: What is the difference between Salofalk GR and Salofalk enema?

A: These products are different formulations of the same active ingredient, mesalazine. Salofalk GR is an oral modified-release granule intended to primarily work throughout the large intestine. Salofalk enema is a rectal liquid formulation designed to deliver the medicine directly to the lower part of the large intestine, such as the rectum and sigmoid colon, for highly localized treatment.

---

Q: Does taking the granules cause weight changes?

A: Weight changes are generally not listed as common or rare side effects in the official regulatory documents for Salofalk GR. In official safety information for mesalazine products, changes in appetite (anorexia) may sometimes be noted as a less frequent metabolic event.

---

Q: Is there any specific monitoring required after starting the drug (e.g., blood tests)?

A: Yes, regulatory documents indicate that a physician will generally order specific blood tests (including liver and kidney function) and a urinary status check both before starting treatment and periodically afterward. Follow-up tests are often recommended shortly after beginning treatment, and then approximately every three months if the results are within normal limits.

How to Store and Dispose of Salofalk GR

Official regulatory documents define specific conditions for storing Salofalk (mesalazine) granules to maintain product stability and safety.

Storage Requirements

The granules must be kept in their original sachet packaging until the time of use; removal before then may compromise the medicine's stability. The product must be stored in a cool, dry place where the temperature stays below 25°C and must be protected from light. To prevent accidental consumption, Salofalk GR must always be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired Salofalk granules should not be disposed of in household waste or wastewater. The proper method for discarding the medicine is to consult a pharmacist for guidance, which ensures disposal aligns with local pharmaceutical waste requirements.